Q3 EPS Estimates for Globus Medical Lifted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Zacks Research upped their Q3 2026 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued on Monday, June 22nd. Zacks Research analyst Team now expects that the medical device company will post earnings per share of $1.16 for the quarter, up from their previous forecast of $1.15. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Globus Medical’s FY2026 earnings at $4.74 EPS, Q1 2027 earnings at $1.12 EPS, Q2 2027 earnings at $1.20 EPS, Q4 2027 earnings at $1.22 EPS, FY2027 earnings at $4.75 EPS and FY2028 earnings at $5.32 EPS.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. Globus Medical’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

Several other equities research analysts also recently commented on GMED. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Truist Financial set a $115.00 price target on shares of Globus Medical in a research report on Wednesday, February 25th. Wells Fargo & Company cut their price target on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Piper Sandler decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Finally, Needham & Company LLC upped their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Globus Medical Stock Down 0.2%

NYSE:GMED opened at $79.05 on Tuesday. The firm has a market capitalization of $10.73 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The stock’s 50 day moving average price is $84.37 and its two-hundred day moving average price is $87.57.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors have recently made changes to their positions in GMED. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the third quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC increased its stake in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares during the period. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.